derma products in the US) this financial year.
“We will continue to file at least three to five derma products every year. We have around 11 oral contraceptives (OC) approved and another eight pending approval. The OC segment will continue to generate increased revenue for us over a period of time before competition intensifies over a three- to five-year period in the OC space,” said Saldanha.
Lupin, which entered the OC segment in September 2011, recently got an FDA approval to sell generic version of Warner Chilcott's Ovcon 35 tablets that had annual US sales of about $22.3 million.
Companies are moving from simple-dosage forms like tablets towards new drug delivery systems, which includes injectables, sprays, aerosols and topicals. These can be used to compete with drugs whose formulation patents have not expired, said analysts.
Indian generic players are also focusing on quality filings over quantity to mitigate the risk of volatility on account of sharp price erosions in the plain-vanilla generic drug market.
Patent cliff is the cluster of time (years) in which a number of significant high sales brand-name drugs lose patent protection. This provides a huge revenue potential for generic players who can enter the market with copycat versions of an innovator drug.